AngioDynamics (ANGO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AngioDynamics Shareholder Approvals and Director Elections
TipRanksNov 15 16:32 ET
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
Zacks Nov 6 10:10 ET
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Zacks Nov 5 09:35 ET
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's Is How to Trade
Zacks Nov 1 09:00 ET
Investors in AngioDynamics (NASDAQ:ANGO) Have Unfortunately Lost 77% Over the Last Three Years
Yahoo FinanceOct 29 11:25 ET
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
Zacks Oct 29 09:50 ET

Comments

Trytosaveabit

Oct 23 07:15

Update

$AngioDynamics (ANGO.US)$ Benzinga· 1 min ago
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

1

Jaguar8

Sep 19 15:48

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant impr...

Jaguar8

May 21 17:30

$AngioDynamics (ANGO.US)$
NEWS
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher...

Moomoo AI

Oct 17, 2023 08:11

AngioDynamics' statutory profits may present an overly positive image of underlying profitability due to unusual items. Be aware of potential company risks.

AngioDynamics' (NASDAQ:ANGO) Earnings Are Weaker Than They Seem

GAME_DAY

Mar 30, 2023 10:36

CURRENT TOP WATCH ⚡️⚡️

VLO TORO ANGO LASE MRK SMTC BOXD SGBX GME EA CNXC
$Valero Energy (VLO.US)$ $TORO CORP (TORO.US)$ $AngioDynamics (ANGO.US)$ $Laser Photonics (LASE.US)$ $Merck & Co (MRK.US)$ $Semtech (SMTC.US)$ $Boxed (BOXD.US)$ $Safe & Green (SGBX.US)$ $GameStop (GME.US)$ $Electronic Arts Inc (EA.US)$ $Concentrix (CNXC.US)$

3

1

ANGO AngioDynamics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target